EGFR and lung adenocarcinoma: Studies have shown that tyrosine kinase inhibitors (TKIs) can effectively prolong the progression-free survival (PFS) of patients with EGFR mutations, and therefore they are widely used in the targeted therapy for lung adenocarcinoma [8, 9].